Oncotech   Report issue

For profit Phase 2 Phase 3
Founded: Ankara Turkey (1995)

Organization Overview

First Clinical Trial
1997
NCT00003253
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Consorzio Oncotech

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Esophageal Neoplasms (Phase 3)

Kidney Neoplasms (Phase 2)

Nausea (Phase 3)

Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 31